Published on in Vol 4 (2023)
Preprints (earlier versions) of this paper are
available at
https://www.medrxiv.org/content/10.1101/2020.08.04.20168112v1, first published
.
Journals
- Majiya H, Aliyu-Paiko M, Balogu V, Musa D, Salihu I, Kawu A, Bashir I, Sani A, Baba J, Muhammad A, Jibril F, Bala E, Obaje N, Aliyu Y, Muhammad R, Mohammed H, Gimba U, Uthman A, Liman H, Alhaji S, James J, Makusidi M, Isah M, Abdullahi I, Ndagi U, Waziri B, Bisallah C, Dadi-Mamud N, Ibrahim K, Adamu A. Authors’ Response to Peer Reviews of “Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study”. JMIRx Med 2023;4:e50515 View
- Ofori S, Schwind J, Sullivan K, Chowell G, Cowling B, Fung I. Modeling the health impact of increasing vaccine coverage and nonpharmaceutical interventions against coronavirus disease 2019 in Ghana. Pathogens and Global Health 2024;118(3):262 View
- Mutevedzi P, Lokotfwako V, Kwatra G, Maphalala G, Baillie V, Dlamini L, Dlamini S, Mhlanga F, Dlamini T, Nhlabatsi N, Nunes M, Zwane S, Madhi S. Prevalence and Levels of Anti-SARS-CoV-2 Antibodies in the Eswatini Population and Subsequent Severity of the Fourth COVID-19 Epidemic Wave. COVID 2024;4(3):317 View
- Ramalan M, Musa B, Abdullahi R, Abdullahi A, Damagum F. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Nigeria: A Systematic Review and Meta Analysis of Seroprevalence Studies. Nigerian Journal of Medicine 2023;32(5):453 View
- Sana A, Djemaï E, De Vreyer P, Thivillon T, Badolo H, Berthé A, Kania D, Roques P. Seroprevalence and risk factors for SARS-CoV-2 infection in middle-sized cities of Burkina Faso: A descriptive cross-sectional study. PLOS ONE 2024;19(8):e0305850 View